全文获取类型
收费全文 | 67031篇 |
免费 | 5585篇 |
国内免费 | 2967篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 3818篇 |
妇产科学 | 319篇 |
基础医学 | 5526篇 |
口腔科学 | 476篇 |
临床医学 | 6536篇 |
内科学 | 11627篇 |
皮肤病学 | 624篇 |
神经病学 | 1471篇 |
特种医学 | 2332篇 |
外国民族医学 | 6篇 |
外科学 | 25189篇 |
综合类 | 8302篇 |
现状与发展 | 14篇 |
一般理论 | 2篇 |
预防医学 | 1481篇 |
眼科学 | 1251篇 |
药学 | 3082篇 |
17篇 | |
中国医学 | 677篇 |
肿瘤学 | 2707篇 |
出版年
2024年 | 61篇 |
2023年 | 808篇 |
2022年 | 1085篇 |
2021年 | 2150篇 |
2020年 | 2198篇 |
2019年 | 2408篇 |
2018年 | 2527篇 |
2017年 | 2322篇 |
2016年 | 2221篇 |
2015年 | 2229篇 |
2014年 | 4007篇 |
2013年 | 4401篇 |
2012年 | 3409篇 |
2011年 | 3981篇 |
2010年 | 3553篇 |
2009年 | 3753篇 |
2008年 | 3855篇 |
2007年 | 3985篇 |
2006年 | 3922篇 |
2005年 | 3451篇 |
2004年 | 2762篇 |
2003年 | 2350篇 |
2002年 | 1843篇 |
2001年 | 1621篇 |
2000年 | 1395篇 |
1999年 | 1075篇 |
1998年 | 980篇 |
1997年 | 860篇 |
1996年 | 805篇 |
1995年 | 702篇 |
1994年 | 759篇 |
1993年 | 464篇 |
1992年 | 595篇 |
1991年 | 440篇 |
1990年 | 331篇 |
1989年 | 298篇 |
1988年 | 336篇 |
1987年 | 222篇 |
1986年 | 171篇 |
1985年 | 189篇 |
1984年 | 151篇 |
1983年 | 80篇 |
1982年 | 135篇 |
1981年 | 115篇 |
1980年 | 116篇 |
1979年 | 88篇 |
1978年 | 75篇 |
1977年 | 72篇 |
1976年 | 59篇 |
1973年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
31.
32.
器官移植术是20世纪出现的针对器官功能衰竭的最有效治疗方法,每年拯救全球超过12万例患者。但供器官短缺的现状,与器官移植技术和辅助药物的发展不匹配,制约了器官移植事业的发展。我国自2015年起已成为全球器官捐献和移植大国之一,2017年公民逝世后器官捐献数量超过5 000例,占全球捐献总量的15%以上。黄洁夫教授总结的器官捐献与移植"中国模式"得到了世界卫生组织、国际移植界的高度重视和充分肯定。本文通过整理全球及各国的器官捐献与移植数据,剖析全球现状与发展趋势,进一步探索我国公民器官捐献的影响因素并提出针对性的应对策略,以期实现我国器官捐献和移植的"自给自足"。 相似文献
33.
《Annals of hepatology》2019,18(2):397-401
We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukemia virus type-1 (HTLV-1) and the recipient was seronegative for HTLV-1 before transplantation. After transplantation, the recipient developed steroid-resistant acute cellular rejection, which was successfully treated using anti-thymocyte globulin, and he was eventually discharged. He underwent spinal surgery twice after the transplantation for the treatment of cervical spondylosis that had been present for a period of 9 months before the transplantation. The surgery improved his gait impairment temporarily. However, his gait impairment progressed, and magnetic resonance imaging revealed multiple sites of myelopathy. He was diagnosed with HAM 16 months after the transplantation. Pulse steroid therapy (1000 mg) was administered over a period of 3 days, and his limb paresis improved. Presently, steroid therapy is being continued, with a plan to eventually taper the dose, and he is being carefully followed up at our institution. Our case suggests that liver transplantation involving an HTLV-1-positive living donor carries the risk of virus transmission and short-term development of HAM after transplantation. 相似文献
34.
[摘要] 目的 评估直接抗病毒药物(direct antivirus agent, DAA)治疗肝移植术后HCV感染复发的有效性和安全性。方法?回顾性分析首都医科大学附属北京佑安医院2011年2月—2018年12月收治的14例肝移植术后HCV感染复发患者的DAA治疗临床数据,比较患者基线与治疗结束后肝肾功能、血常规、凝血功能、病毒学水平以及无创纤维化评分天冬氨酸转氨酶血小板比率指数(aspartate aminotransferase-platelet ratio index, APRI)的差异。利用电子病历系统和电话随访收集患者治疗期间不良反应发生情况。结果?所有患者均在治疗结束时达到病毒学清除,12周、24周持续病毒学应答率均为100%,DAA治疗后随访17~44个月,期间均未见病毒学复发。与基线水平相比,治疗终点时ALT、AST、TBIL、γ-谷氨酰转移酶以及无创纤维化评分APRI显著下降,WBC、HGB、PLT、CRE、肾小球滤过率和血糖等指标均未见显著变化。DAA治疗期间共3例患者发生不良反应,均为轻度,可自然缓解。结论?肝移植术后HCV感染复发的DAA治疗是安全有效的。 相似文献
35.
36.
37.
《Clinical genitourinary cancer》2020,18(2):88-94.e2
Recent meta-analyses on checkpoint inhibitors in cancer report conflicting data regarding the association of patient gender with inhibitor efficacy. In advanced kidney cancer, checkpoint inhibitors have shown improved outcomes in first- and second-line settings compared with standard of care, but the role of patient gender on treatment outcome is unclear. We aimed to assess the efficacy of immunotherapy according to patient gender in advanced kidney cancer.We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was performed using PubMed, Scopus, Web of Science, and The Cochrane Library to identify eligible studies published through February 16, 2019. Studies were included if they reported on the differential outcomes of male and female patients with metastatic kidney cancer receiving immunotherapy. Our outcomes of interest were overall survival (OS) or progression-free survival (PFS).Four randomized controlled trials comprising a total of 3664 patients (2715 males and 949 females) met our inclusion criteria. Both men and women with metastatic kidney cancer had an OS and PFS advantage with immunotherapy compared with standard-of-care, but no statistically significant difference between the genders was observed (OS hazard ratio [HR] for men, 0.69; 95% confidence interval [CI], 0.59-0.8; P = .40; HR for women, 0.62; 95% CI, 0.48-0.81; P = .13; PFS HR for men, 0.7; 95% CI, 0.59-0.82; P = .24; HR for women, 0.68; 95% CI, 0.52-0.90; P = .105).In patients with advanced kidney cancer receiving checkpoint inhibitors, there seems to be no association of patient gender with treatment outcome. 相似文献
38.
39.
《Clinical genitourinary cancer》2020,18(1):56-61
BackgroundClear-cell renal cell carcinoma (ccRCC) is one of the most common malignancies in humans and is usually associated with poor outcomes. Cancers are considered to be genetic diseases. Therefore, a better understanding of genetic alterations that are related to disease progression or poor prognosis can help to more precisely identify high-risk patients and treat them more effectively. The aim of this study was to examine the frequency of whole chromosome 9 loss (monosomy of chromosome 9) and its prognostic value in patients with ccRCC.Materials and MethodsSingle nucleotide polymorphism-based chromosome microarray (CMA) analysis was performed on 103 resected specimens from patients with ccRCC who had undergone partial or radical nephrectomy between January 2002 and March 2017 at Fox Chase Cancer Center. Monosomy 9 was correlated with clinicopathologic parameters and recurrence-free survival.ResultsChromosome 9 loss was detected in 31 (30%) of 103 tumors. Tumors with chromosome 9 loss had higher histologic grade (3 and 4; P < .001) and pathologic stage (P < .001). In 59 patients with non-metastatic ccRCC, chromosome 9 loss was also associated with higher recurrence rate and shorter recurrence-free survival (RFS) (12-month RFS, 77.8%; 95% confidence interval, 36.5%-93.9% for chromosome 9 loss vs. 95.7%; 95% confidence interval, 84.0%-98.9% for no loss; P = .002).ConclusionsChromosome 9 loss was found in 30% of patients with ccRCC and correlated with higher grade, advanced stage, and shorter RFS in patients with Stage I to III ccRCC. 相似文献
40.